Bionomics’ Half-Year Report
February 23, 2023 06:00 ET
|
Bionomics Ltd
ADELAIDE, Australia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX), today announced its FY2023 report for the half-year ended 31 December 2022. This period represented...
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
February 22, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future...
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
January 31, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Quarterly Activities and Cashflow Report
January 30, 2023 18:23 ET
|
Bionomics Ltd
ADELAIDE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO,), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel,...
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
January 05, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
December 18, 2022 19:34 ET
|
Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to...
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
December 15, 2022 18:35 ET
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 02, 2022 06:00 ET
|
Bionomics Ltd
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022 06:35 ET
|
Axsome Therapeutics, Inc.
AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of...